Biocytogen Pharmaceuticals (2315) Releases 2025 Preliminary Financial Results, Operating Revenue Reaches RMB1.38 Billion

Bulletin Express02-26

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (2315) disclosed its unaudited preliminary financial figures for the year 2025. According to the announcement, total operating revenue stood at RMB1.38 billion, reflecting a 40.63% year-on-year increase. Net profit attributable to owners of the company came in at RMB173.20 million, while after deducting non-recurring profit or loss, net profit stood at RMB116.08 million.

During this period, the company’s total assets reached RMB3.72 billion, marking a 54.20% surge compared with the start of the reporting period. Equity attributable to owners of the company was RMB2.17 billion, up 160.76% from the beginning of the year. Management attributes these gains to the continuous expansion in overseas markets, the steady recovery of the domestic biopharmaceutical sector, and strong research and development investments. The listing of A shares, which generated net proceeds of RMB1.14 billion, also contributed to enhanced capital structure.

The figures presented are preliminary and may differ from those in the final audited results. Investors should refer to the forthcoming 2025 annual report for complete, audited data.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1153125640?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-26 17:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1153125640","market":"hk","top_or_hot":-1,"title":"Biocytogen Pharmaceuticals (2315) Releases 2025 Preliminary Financial Results, Operating Revenue Reaches RMB1.38 Billion","media":"Bulletin Express","content":"<p>Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (2315) disclosed its unaudited preliminary financial figures for the year 2025. According to the announcement, total operating revenue stood at RMB1.38 billion, reflecting a 40.63% year-on-year increase. Net profit attributable to owners of the company came in at RMB173.20 million, while after deducting non-recurring profit or loss, net profit stood at RMB116.08 million.</p>\n<p>During this period, the company’s total assets reached RMB3.72 billion, marking a 54.20% surge compared with the start of the reporting period. Equity attributable to owners of the company was RMB2.17 billion, up 160.76% from the beginning of the year. Management attributes these gains to the continuous expansion in overseas markets, the steady recovery of the domestic biopharmaceutical sector, and strong research and development investments. The listing of A shares, which generated net proceeds of RMB1.14 billion, also contributed to enhanced capital structure.</p>\n<p>The figures presented are preliminary and may differ from those in the final audited results. Investors should refer to the forthcoming 2025 annual report for complete, audited data.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biocytogen Pharmaceuticals (2315) Releases 2025 Preliminary Financial Results, Operating Revenue Reaches RMB1.38 Billion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiocytogen Pharmaceuticals (2315) Releases 2025 Preliminary Financial Results, Operating Revenue Reaches RMB1.38 Billion\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-02-26 17:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (2315) disclosed its unaudited preliminary financial figures for the year 2025. According to the announcement, total operating revenue stood at RMB1.38 billion, reflecting a 40.63% year-on-year increase. Net profit attributable to owners of the company came in at RMB173.20 million, while after deducting non-recurring profit or loss, net profit stood at RMB116.08 million.</p>\n<p>During this period, the company’s total assets reached RMB3.72 billion, marking a 54.20% surge compared with the start of the reporting period. Equity attributable to owners of the company was RMB2.17 billion, up 160.76% from the beginning of the year. Management attributes these gains to the continuous expansion in overseas markets, the steady recovery of the domestic biopharmaceutical sector, and strong research and development investments. The listing of A shares, which generated net proceeds of RMB1.14 billion, also contributed to enhanced capital structure.</p>\n<p>The figures presented are preliminary and may differ from those in the final audited results. Investors should refer to the forthcoming 2025 annual report for complete, audited data.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02315","symbol_name":"百奥赛图-B","start_time":0,"source_url":"","article_id":"1153125640","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1153125640","pubTimestamp":1772096544,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (2315) disclosed its unaudited preliminary financial figures for the year 2025. According to the announcement, total operating revenue stood at RMB1.38...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02315":"百奥赛图-B"},"translate_title":"百奥赛图药业(2315)发布2025年初步财务业绩，营业收入达人民币13.8亿元","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02315":1},"content_text":"Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (2315) disclosed its unaudited preliminary financial figures for the year 2025. According to the announcement, total operating revenue stood at RMB1.38 billion, reflecting a 40.63% year-on-year increase. Net profit attributable to owners of the company came in at RMB173.20 million, while after deducting non-recurring profit or loss, net profit stood at RMB116.08 million.\nDuring this period, the company’s total assets reached RMB3.72 billion, marking a 54.20% surge compared with the start of the reporting period. Equity attributable to owners of the company was RMB2.17 billion, up 160.76% from the beginning of the year. Management attributes these gains to the continuous expansion in overseas markets, the steady recovery of the domestic biopharmaceutical sector, and strong research and development investments. The listing of A shares, which generated net proceeds of RMB1.14 billion, also contributed to enhanced capital structure.\nThe figures presented are preliminary and may differ from those in the final audited results. Investors should refer to the forthcoming 2025 annual report for complete, audited data.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1153125640","isCrawlerRequest":true}